ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.54
-0.09%
US Tech 100
19,220.00
-0.20%
S&P 500
5,464.62
-0.16%
US Dollar vs CAD
1.36967
-0.02%
Bitcoin
64,100.67
-0.22%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alnylam Pharmaceuticals Inc (ALNY)

  7. Alnylam Pharmaceuticals Inc (ALNY) News

ALNY

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALNY
DateTimeSourceHeadlineSymbolCompany
05/31/20246:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/29/20243:01PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/20/20243:34PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/20/20243:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/20/20243:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/20/20243:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/20/20243:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/20/20243:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/20/20243:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/20/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/20/20243:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/20/20243:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/20/20243:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/07/20247:00AMBusiness WireAlnylam Issues 2023 Corporate Responsibility ReportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/02/20247:00AMBusiness WireAlnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
04/30/20246:00AMPR Newswire (Canada)Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including AustraliaNASDAQ:ALNYAlnylam Pharmaceuticals Inc
04/30/20246:00AMPR Newswire (US)Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including AustraliaNASDAQ:ALNYAlnylam Pharmaceuticals Inc
04/18/20247:00AMBusiness WireAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
04/07/20247:00AMBusiness WireAlnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled HypertensionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
03/20/20247:00AMBusiness WireAlnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific SessionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
03/13/20246:30AMBusiness WireAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive DiseaseNASDAQ:ALNYAlnylam Pharmaceuticals Inc
03/06/20245:50AMBusiness WireAlnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegenNASDAQ:ALNYAlnylam Pharmaceuticals Inc
03/05/20244:39PMBusiness WireAlnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standardsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
03/05/20243:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
03/05/20243:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
03/05/20243:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
03/05/20243:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
03/05/20246:30AMBusiness WireAlnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care AntihypertensivesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
03/04/20243:33PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/29/20243:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ALNY

Your Recent History

TG
DL19V5
Deutsche Bank
LSE
IJPD
Ish Japan $ Hdg
LBNK
SDTUSDT
Stake DAO Token
TG
A281HV
Belfius Bank
BIT
P1YEN6
NLBNPIT1YEN6 20240621 380
DOWI
MTS
USOTC
BHOOY
Boohoo (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved